Skip to content
Disclosery

Logos Global Management LP

Follow

13F filer, CIK 1792126, San Francisco, CA

Logos Global Management LP reported $2,002,914,879 across 66 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-15. Its ten largest share positions make up 50.91% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001172661-26-002196

Period
2026-03-31
Reported value
$2B
Holdings
66
Top 10 weight
50.91%
New
15
Sold out
18

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CNTAadded+1,925,000$76.5M
UTHRnew+80,000$47.4M
MDGLnew+85,000$44.5M
TERNadded+750,000$39.5M
CYTKadded+575,000$37.9M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CDTXexited-310,000-$68.5M
RNAMexited-500,000-$36.1M
JAZZexited-200,000-$34M
ERASreduced-1,850,000-$29.9M
PRAXreduced-90,000-$29M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001172661-26-002196, largest first. % of portfolio is the value over $1,942,024,879, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,200,000 shares; 2024Q4: 1,450,000 shares; 2025Q1: 1,600,000 shares; 2025Q2: 1,700,000 shares; 2025Q3: 1,750,000 shares; 2025Q4: 2,000,000 shares; 2026Q1: 2,000,000 shares 2,000,000$194M10.02%0Timeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 10,900,000 shares; 2024Q4: 12,500,000 shares; 2025Q1: 13,000,000 shares; 2025Q2: 15,000,000 shares; 2025Q3: 15,150,000 shares; 2025Q4: 13,000,000 shares; 2026Q1: 11,150,000 shares 11,150,000$180M9.29%-1,850,000Timeline
IDYAIDEAYA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 2,100,000 shares; 2024Q4: 3,000,000 shares; 2025Q1: 3,500,000 shares; 2025Q2: 3,345,000 shares; 2025Q3: 2,250,000 shares; 2025Q4: 3,125,000 shares; 2026Q1: 3,450,000 shares 3,450,000$115M5.92%+325,000Timeline
PRAXPRAXIS PRECISION MEDICINES IQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 225,000 shares; 2025Q3: 125,000 shares; 2025Q4: 375,000 shares; 2026Q1: 285,000 shares 285,000$91.8M4.73%-90,000Timeline
CNTACENTESSA PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 525,000 shares; 2025Q4: 200,000 shares; 2026Q1: 2,125,000 shares 2,125,000$84.4M4.35%+1,925,000Timeline
TERNTERNS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 750,000 shares; 2026Q1: 1,500,000 shares 1,500,000$79.1M4.07%+750,000Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 415,000 shares; 2025Q4: 400,000 shares; 2026Q1: 675,000 shares 675,000$75.2M3.87%+275,000Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 950,000 shares; 2025Q4: 4,200,000 shares; 2026Q1: 3,000,000 shares 3,000,000$62.8M3.23%-1,200,000Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 400,000 shares; 2024Q4: 900,000 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 300,000 shares; 2026Q1: 875,000 shares 875,000$57.7M2.97%+575,000Timeline
OLMAOLEMA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 3,208,875 shares; 2024Q4: 3,208,875 shares; 2025Q1: 3,208,875 shares; 2025Q2: 3,208,875 shares; 2025Q3: 3,208,875 shares; 2025Q4: 3,208,875 shares; 2026Q1: 3,208,875 shares 3,208,875$47.8M2.46%0Timeline
UTHRUNITED THERAPEUTICS CORP DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 85,000 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 80,000 shares 80,000$47.4M2.44%newTimeline
IMCRIMMUNOCORE HLDGS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 575,000 shares; 2025Q3: 850,000 shares; 2025Q4: 850,000 shares; 2026Q1: 1,500,000 shares 1,500,000$45.2M2.33%+650,000Timeline
MDGLMADRIGAL PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 50,000 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 85,000 shares 85,000$44.5M2.29%newTimeline
RYTMRHYTHM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 130,000 shares; 2025Q3: 200,000 shares; 2025Q4: 190,000 shares; 2026Q1: 450,000 shares 450,000$39.1M2.02%+260,000Timeline
CGONCG ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 200,000 shares; 2026Q1: 575,000 shares 575,000$38.9M2%+375,000Timeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 936,914 shares; 2025Q2: 611,914 shares; 2025Q3: 1,227,300 shares; 2025Q4: 950,000 shares; 2026Q1: 1,235,000 shares 1,235,000$36.9M1.9%+285,000Timeline
BIIBBIOGEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 200,000 shares; 2025Q3: 100,000 shares; 2025Q4: 200,000 shares; 2026Q1: 200,000 shares 200,000$36.7M1.89%0Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 935,000 shares; 2024Q4: 200,000 shares; 2025Q1: 394,342 shares; 2025Q2: 700,000 shares; 2025Q3: 450,000 shares; 2025Q4: 510,000 shares; 2026Q1: 560,000 shares 560,000$35.8M1.84%+50,000Timeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 200,000 shares; 2025Q4: 315,000 shares; 2026Q1: 400,000 shares 400,000$33.6M1.73%+85,000Timeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 3,500,000 shares; 2024Q4: 3,500,000 shares; 2025Q1: 2,300,000 shares; 2025Q2: 2,200,000 shares; 2025Q3: 3,250,000 shares; 2025Q4: 3,500,000 shares; 2026Q1: 3,850,000 shares 3,850,000$32.6M1.68%+350,000Timeline
TYRATYRA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 210,000 shares; 2026Q1: 850,000 shares 850,000$32.6M1.68%+640,000Timeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 2,750,000 shares; 2024Q4: 1,250,000 shares; 2025Q1: 424,715 shares; 2025Q2: 850,000 shares; 2025Q3: 2,200,000 shares; 2025Q4: 1,550,000 shares; 2026Q1: 2,400,000 shares 2,400,000$28.6M1.47%+850,000Timeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 350,000 shares; 2025Q2: 200,000 shares; 2025Q3: not reported; 2025Q4: 1,750,000 shares; 2026Q1: 1,500,000 shares 1,500,000$28M1.44%-250,000Timeline
IMVTIMMUNOVANT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,100,000 shares; 2024Q4: 300,000 shares; 2025Q1: 275,000 shares; 2025Q2: 275,000 shares; 2025Q3: 275,000 shares; 2025Q4: 1,375,000 shares; 2026Q1: 1,075,000 shares 1,075,000$26.7M1.38%-300,000Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 650,000 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 450,000 shares 450,000$26.2M1.35%newTimeline
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,200,000 shares 1,200,000$25.9M1.33%newTimeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 160,000 shares; 2024Q4: 450,000 shares; 2025Q1: 500,000 shares; 2025Q2: 1,900,000 shares; 2025Q3: 2,400,000 shares; 2025Q4: 1,250,000 shares; 2026Q1: 1,400,000 shares 1,400,000$25.4M1.31%+150,000Timeline
GPCRSTRUCTURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,250,000 shares; 2024Q4: 700,000 shares; 2025Q1: 425,000 shares; 2025Q2: 850,000 shares; 2025Q3: 850,000 shares; 2025Q4: 600,000 shares; 2026Q1: 500,000 shares 500,000$24.1M1.24%-100,000Timeline
LBRXLB PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,130,000 shares; 2025Q4: 1,200,000 shares; 2026Q1: 915,000 shares 915,000$22.6M1.16%-285,000Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 495,000 shares; 2024Q4: 140,000 shares; 2025Q1: 240,000 shares; 2025Q2: 350,000 shares; 2025Q3: 340,000 shares; 2025Q4: 340,000 shares; 2026Q1: 540,000 shares 540,000$21.2M1.09%+200,000Timeline
DSGNDESIGN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 4,217,627 shares; 2024Q4: 4,217,627 shares; 2025Q1: 4,217,627 shares; 2025Q2: 4,217,627 shares; 2025Q3: 3,655,000 shares; 2025Q4: 2,500,000 shares; 2026Q1: 1,950,000 shares 1,950,000$20.7M1.07%-550,000Timeline
NERVMINERVA NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 3,311,000 shares; 2026Q1: 3,215,000 shares 3,215,000$19.4M1%-96,000Timeline
NAMSNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 450,000 shares; 2026Q1: 600,000 shares 600,000$19.2M0.99%+150,000Timeline
MIRMMIRUM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 225,000 shares; 2026Q1: 200,000 shares 200,000$18.5M0.95%-25,000Timeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 300,000 shares; 2024Q4: 300,000 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 625,000 shares; 2025Q4: 650,000 shares; 2026Q1: 300,000 shares 300,000$17.4M0.9%-350,000Timeline
ACADACADIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 850,000 shares; 2026Q1: 750,000 shares 750,000$16.7M0.86%-100,000Timeline
CMPXCOMPASS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,050,000 shares; 2025Q4: 1,150,000 shares; 2026Q1: 3,150,000 shares 3,150,000$16.7M0.86%+2,000,000Timeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 900,000 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 600,000 shares; 2025Q3: not reported; 2025Q4: 350,000 shares; 2026Q1: 450,000 shares 450,000$14.3M0.74%+100,000Timeline
JANXJANUX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,000,000 shares; 2024Q4: 1,250,000 shares; 2025Q1: 1,650,000 shares; 2025Q2: 1,000,000 shares; 2025Q3: 935,000 shares; 2025Q4: 1,000,000 shares; 2026Q1: 1,000,000 shares 1,000,000$13.9M0.72%0Timeline
VORVOR BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 100,000 shares; 2026Q1: 750,000 shares 750,000$13.4M0.69%+650,000Timeline
ALKSALKERMES PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 500,000 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 350,000 shares 350,000$12.4M0.64%newTimeline
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 450,000 shares; 2026Q1: 950,000 shares 950,000$12M0.62%+500,000Timeline
IMMXIMMIX BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,000,000 shares; 2026Q1: 1,225,000 shares 1,225,000$11.2M0.57%+225,000Timeline
TENXTENAX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 625,000 shares 625,000$9.99M0.51%newTimeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,450,000 shares; 2025Q4: 950,000 shares; 2026Q1: 700,000 shares 700,000$9.73M0.5%-250,000Timeline
CBIOCRESCENT BIOPHARMA INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 553,686 shares; 2025Q3: 600,000 shares; 2025Q4: 600,000 shares; 2026Q1: 482,500 shares 482,500$8.86M0.46%-117,500Timeline
SLNOSOLENO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 350,000 shares; 2025Q1: 250,000 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 300,000 shares; 2026Q1: 250,000 shares 250,000$8.37M0.43%-50,000Timeline
AVBPARRIVENT BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 350,000 shares 350,000$8.07M0.42%newTimeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 750,000 shares 750,000$7.46M0.38%newTimeline
CRVSCORVUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 500,000 shares; 2026Q1: 450,000 shares 450,000$6.58M0.34%-50,000Timeline
MGTXMEIRAGTX HLDGS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 700,000 shares 700,000$6.06M0.31%newTimeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 625,000 shares; 2025Q3: 625,000 shares; 2025Q4: 395,000 shares; 2026Q1: 400,000 shares 400,000$5.62M0.29%+5,000Timeline
VSTMVERASTEM INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,000,000 shares; 2025Q3: 4,050,000 shares; 2025Q4: 1,700,000 shares; 2026Q1: 1,000,000 shares 1,000,000$5.3M0.27%-700,000Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 539,079 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 300,000 shares 300,000$4.48M0.23%newTimeline
UNCYUNICYCIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 473,562 shares; 2025Q3: 473,563 shares; 2025Q4: 473,563 shares; 2026Q1: 473,563 shares 473,563$3.12M0.16%0Timeline
IBIOIBIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,000,000 shares; 2026Q1: 1,300,000 shares 1,300,000$2.47M0.13%-700,000Timeline
PTNPALATIN TECHNOLOGIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 140,000 shares; 2026Q1: 140,000 shares 140,000$2.44M0.13%0Timeline
ACRSACLARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 2,222,222 shares; 2025Q1: 2,222,222 shares; 2025Q2: 1,850,000 shares; 2025Q3: 1,500,000 shares; 2025Q4: 600,000 shares; 2026Q1: 500,000 shares 500,000$1.88M0.1%-100,000Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 150,000 shares; 2025Q4: 100,000 shares; 2026Q1: 65,000 shares 65,000$1.84M0.09%-35,000Timeline
MANEVERADERMICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 25,000 shares 25,000$1.58M0.08%newTimeline
FTHFAETH THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 30,000 shares 30,000$946K0.05%newTimeline
SEPNSEPTERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 134,202 shares; 2025Q1: 134,202 shares; 2025Q2: 109,202 shares; 2025Q3: 83,548 shares; 2025Q4: 23,548 shares; 2026Q1: 23,548 shares 23,548$566K0.03%0Timeline
GUTSFRACTYL HEALTH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 500,000 shares; 2025Q4: 1,100,000 shares; 2026Q1: 1,000,000 shares 1,000,000$458K0.02%-100,000Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
TERNTERNS PHARMACEUTICALS INC Stockcall500,000$26.4Mnew
ELVNENLIVEN THERAPEUTICS INC Stockcall500,000$19.6Mnew
AVTXAVALO THERAPEUTICS INC COMMON STOCKcall1,000,000$14.9Mnew

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
RVMDREVOLUTION MEDICINES INC1,000,000$79.7Mcall
CDTXCIDARA THERAPEUTICS INC310,000$68.5Mshares
RNAMAVIDITY BIOSCIENCES INC500,000$36.1Mshares
JAZZJAZZ PHARMACEUTICALS PLC200,000$34Mshares
APLSAPELLIS PHARMACEUTICALS INC1,000,000$25.1Mcall
RCUSARCUS BIOSCIENCES INC1,050,000$25Mcall
QUREUNIQURE NV675,000$16.2Mshares
IDYAIDEAYA BIOSCIENCES INC450,000$15.6Mcall
KNSAKINIKSA PHARMACEUTICALS INTL350,000$14.4Mshares
KYMRKYMERA THERAPEUTICS INC130,000$10.1Mshares
NRIXNURIX THERAPEUTICS INC500,000$9.48Mshares
IMTXIMMATICS N.V850,000$8.93Mcall
ACLXARCELLX INC115,000$7.5Mshares
NGNENEUROGENE INC195,000$4.02Mshares
DAWNDAY ONE BIOPHARMACEUTICALS I300,000$2.8Mshares
MREOMEREO BIOPHARMA GROUP PLC1,850,000$771Kshares
DBVTDBV TECHNOLOGIES S A25,000$479Kshares
NUVATION BIO INCNUVATION BIO INC66,666$22Kshares

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001172661-26-002196 base2026-05-15acceptance time not in the bulk data set